Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
05 Jun 2022
Historique:
received: 19 01 2022
revised: 28 03 2022
accepted: 14 04 2022
pubmed: 25 4 2022
medline: 12 5 2022
entrez: 24 4 2022
Statut: ppublish

Résumé

A robust analytical method based on liquid chromatography coupled to tandem mass spectrometry was developed and validated to quantify rifapentine and 25-O-desacetyl rifapentine in human breast milk to aid in determining the breastfed infant risk to the excreted drug in human milk. Samples were extracted by a combination of protein precipitation and solid phase extraction using rifampicin-d3 as an internal standard. An Agilent® Poroshell 120 EC-C18 (4.6 mm × 50 mm, 2.7 µm) column was used for chromatographic separation employing an isocratic mobile phase consisting of acetonitrile: methanol: 0.1% formic acid (55/5/40, v/v/v) at a flow rate of 450 µL/min, and with a total run time of four minutes. Mass detection was on an AB Sciex API 4000 mass spectrometer using electrospray ionization in the positive mode and based on multiple reaction monitoring data acquisition. Rifapentine was accurately quantified across a concentration range of 2.00-2000 ng/mL and 25-O-desacetyl rifapentine from 4.00 to 2000 ng/mL. During validation, the inter- and intra-day accuracy and precision at the tested QC concentrations (N = 18) for rifapentine were between 97.4% and 100.6%, and 3.1% and 8.3%, respectively. The inter- and intra-day accuracy and precision for 25-O-desacetyl rifapentine were between 96.4% and 106.3%, and 6.7% and 11.8%, respectively. No significant matrix effects were observed, and the method was shown to be specific for rifapentine and 25-O-desacetyl rifapentine. Human milk samples (N = 22) generated during a phase I/II clinical trial were successfully analysed for rifapentine and 25-O-desacetyl rifapentine using this validated method. Concentrations for rifapentine and 25-O-desacetyl rifapentine in human milk samples (N = 22) ranged from 11.2-1180 ng/mL and 7.11-573 ng/mL, respectively.

Identifiants

pubmed: 35462285
pii: S0731-7085(22)00195-9
doi: 10.1016/j.jpba.2022.114774
pmc: PMC9871952
mid: NIHMS1862049
pii:
doi:

Substances chimiques

Rifampin VJT6J7R4TR
rifapentine XJM390A33U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114774

Subventions

Organisme : NIAID NIH HHS
ID : K24 AI150349
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275201800001C
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068632
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068616
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI106716
Pays : United States
Organisme : NICHD NIH HHS
ID : HHSN275201800001I
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Références

J Pharm Biomed Anal. 2015 Feb;104:55-61
pubmed: 25481085
Anal Chem. 1998 Mar 1;70(5):882-9
pubmed: 9511465
Am J Med Sci. 2008 Feb;335(2):126-36
pubmed: 18277121
Antimicrob Agents Chemother. 2015 Feb;59(2):1219-24
pubmed: 25512422
Clin Pharmacokinet. 2001;40(5):327-41
pubmed: 11432536
Clin Infect Dis. 2022 May 3;74(9):1604-1613
pubmed: 34323955
Ther Drug Monit. 2008 Oct;30(5):611-9
pubmed: 18758393
Rapid Commun Mass Spectrom. 2020 Apr 30;34(8):e8667
pubmed: 31800129
Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52
pubmed: 24957823
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S151-S163
pubmed: 30248201
Anal Bioanal Chem. 2010 Jun;397(3):1157-79
pubmed: 20386886
Biochem Pharmacol. 2011 Dec 1;82(11):1747-56
pubmed: 21856291
J Antimicrob Chemother. 2015 Feb;70(2):555-61
pubmed: 25326089
Chem Biol Interact. 1997 Nov 6;107(1-2):17-30
pubmed: 9402947
Br J Clin Pharmacol. 2008 Mar;65(3):418-22
pubmed: 18093257
Antimicrob Agents Chemother. 2014 Nov;58(11):6747-57
pubmed: 25182637
Anal Chem. 2003 Jul 1;75(13):3019-30
pubmed: 12964746
Clin Pharmacol Ther. 2012 May;91(5):881-8
pubmed: 22472995

Auteurs

Buyisile Mkhize (B)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Tracy Kellermann (T)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa; Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa.

Jennifer Norman (J)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Sandra Castel (S)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Anton Joubert (A)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Marthinus van der Merwe (M)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Kelly E Dooley (KE)

Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Jyoti S Mathad (JS)

Department of Medicine and Obstetrics and Gynecology, Center for Global Health, Weill Cornell Medicine, New York, NY, USA.

Lubbe Wiesner (L)

Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: lubbe.wiesner@uct.ac.za.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH